多只债基提前结束募集；公募调研热度持续升温丨天赐良基早参

Group 1 - Jiashi Fund announced the renaming of 22 index products to enhance investor recognition and improve ETF investment convenience, effective June 17 [1] - The renaming strategy involves adopting a format of "benchmark index + ETF + manager name" for better identification of index products [1] Group 2 - Active equity funds have shown significant performance differentiation this year, with 69.46% of 4,554 equity funds achieving net value growth, up from 42.07% in the same period last year [2] - The top-performing active equity funds have recorded net value growth rates exceeding 87%, while the bottom performers have seen losses exceeding 24% [2] Group 3 - As of the end of Q1 2025, the total scale of enterprise annuity funds reached 3.73 trillion yuan, with a net investment asset value of 3.70 trillion yuan, and a three-year cumulative return of 7.46% [3] - Fixed income combinations within single plans reported a three-year cumulative return of 10.8%, while equity-inclusive combinations reported 7.13% [3] Group 4 - Several bond funds, including the Roadbo Fund and Jingguan Taifu Fund, have ended their fundraising early due to exceeding subscription limits, with the Roadbo Fund closing on June 13 [4][5] Group 5 - Public fund research activity has increased, with 129 public fund institutions conducting 780 research sessions on A-share listed companies, marking a 17.82% increase from the previous week [6] - The technology sector, particularly the electronics industry, received the most attention, with 160 research sessions conducted [7] Group 6 - Xu Chengcheng has been appointed as the fund manager for the Xingye CSI A500 ETF Link, bringing 21 years of experience in the securities industry [8] Group 7 - On June 17, the market experienced fluctuations, with the Shanghai Composite Index down 0.04% and total trading volume at 1.21 trillion yuan, a decrease of 78.7 billion yuan from the previous trading day [9] - The National 2000 ETF led gains with a 1.92% increase, while Hong Kong's innovative drug-related ETFs saw declines of up to 5.24% [10]